Thursday , November 23 2017

Question 873

In head-to-head trials of dipeptidyl peptidase 4 (DPP-4) inhibitors vs glucagon-like peptide 1 (GLP-1) receptor agonists, GLP-1 receptor agonists showed more favorable outcomes in all of the following areas except which one of the following?

Correct

Answer: B. Greater tolerability

GLP-1 receptor agonists showed more favorable outcomes than DPP-4 inhibitors in terms of glycemic control, weight loss, beta-cell function, and reduction of postprandial triglycerides. However, DPP-4 inhibitors offered greater tolerability because GLP-1 receptor agonists were associated with a higher incidence of mild to moderate gastrointestinal adverse events.  Nauck M. Diabetes Obes Metab. 2016;18(3):203-216.

Incorrect